KATIE SALVATI: Open Payments
NPI 1083005409 · LINCOLN, NE. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$1,495 in 92 payments from 19 companies in 2025. Trend: 2023 $1,264 · 2024 $1,255 · 2025 $1,495
Food & beverage: $1,495
| Company | Payments | Amount |
|---|---|---|
| Lundbeck LLC | 19 | $255 |
| Otsuka America Pharmaceutical, Inc. | 17 | $240 |
| Teva Pharmaceuticals USA, Inc. | 13 | $158 |
| Alkermes, Inc. | 8 | $144 |
| Axsome Therapeutics, Inc. | 6 | $120 |
| ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | 4 | $90 |
| Biogen, Inc. | 3 | $70 |
| Neos Therapeutics, LP | 4 | $69 |
| Supernus Pharmaceuticals, Inc. | 3 | $69 |
| E.R. Squibb & Sons, L.L.C. | 3 | $53 |
Products named: REXULTI, ARISTADA, CAPLYTA, AUSTEDO XR, ABILIFY MAINTENA, UZEDY, ZURZUVAE, Qelbree.
Industry payments across NE — which companies pay providers there.
